[Cytokines and T cell differentiation in systemic sclerosis].

[1]  S. Shete,et al.  Association of Interleukin 23 Receptor Polymorphisms with Anti-Topoisomerase-I Positivity and Pulmonary Hypertension in Systemic Sclerosis , 2009, The Journal of Rheumatology.

[2]  H. Spits,et al.  Identification of a human helper T cell population that has abundant production of interleukin 22 and is distinct from TH-17, TH1 and TH2 cells , 2009, Nature Immunology.

[3]  D. Jarrossay,et al.  Production of interleukin 22 but not interleukin 17 by a subset of human skin-homing memory T cells , 2009, Nature Immunology.

[4]  R. Lafyatis,et al.  The Pronounced Th17 Profile in Systemic Sclerosis (SSc) Together with Intracellular Expression of TGFβ and IFNγ Distinguishes SSc Phenotypes , 2009, PloS one.

[5]  Lisa C. Zaba,et al.  IL-22-producing "T22" T cells account for upregulated IL-22 in atopic dermatitis despite reduced IL-17-producing TH17 T cells. , 2009, The Journal of allergy and clinical immunology.

[6]  T. Medsger,et al.  Effector CD8+ T cells in systemic sclerosis patients produce abnormally high levels of interleukin-13 associated with increased skin fibrosis. , 2009, Arthritis and rheumatism.

[7]  Thomas Korn,et al.  IL-17 and Th17 Cells. , 2009, Annual review of immunology.

[8]  A. Abbas,et al.  Distinct roles of helper T-cell subsets in a systemic autoimmune disease. , 2009, Blood.

[9]  C. Weaver,et al.  Diversity in the contribution of interleukin‐10 to T‐cell‐mediated immune regulation , 2008, Immunological reviews.

[10]  Christoph Wilhelm,et al.  Transforming growth factor-β 'reprograms' the differentiation of T helper 2 cells and promotes an interleukin 9–producing subset , 2008, Nature Immunology.

[11]  C. Denton,et al.  An open-label pilot study of infliximab therapy in diffuse cutaneous systemic sclerosis , 2008, Annals of the rheumatic diseases.

[12]  E. Ferrannini,et al.  Th1 and Th2 chemokine serum levels in systemic sclerosis in the presence or absence of autoimmune thyroiditis. , 2008, The Journal of rheumatology.

[13]  L. Messerini,et al.  Endothelial/lymphocyte activation leads to prominent CD4+ T cell infiltration in the gastric mucosa of patients with systemic sclerosis. , 2008, Arthritis and rheumatism.

[14]  M. González-Gay,et al.  The interleukin 23 receptor gene does not confer risk to systemic sclerosis and is not associated with systemic sclerosis disease phenotype , 2008, Annals of the rheumatic diseases.

[15]  D. Campbell,et al.  Foxp3+ regulatory T cells maintain immune homeostasis in the skin , 2008, The Journal of experimental medicine.

[16]  M. Fujimoto,et al.  Clinical association of serum interleukin-17 levels in systemic sclerosis: is systemic sclerosis a Th17 disease? , 2008, Journal of dermatological science.

[17]  T. Malek,et al.  The biology of interleukin-2. , 2008, Annual review of immunology.

[18]  U. Demkow,et al.  TNFalpha and INFgamma inducing capacity of sera from patients with interstitial lung disease in relation to its angiogenesis activity. , 2007, Journal of physiology and pharmacology : an official journal of the Polish Physiological Society.

[19]  Shimon Sakaguchi,et al.  Natural regulatory T cells: mechanisms of suppression. , 2007, Trends in molecular medicine.

[20]  P. Valdez,et al.  Interleukin-22, a TH17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis , 2007, Nature.

[21]  A. Gabrielli,et al.  Bone marrow endothelial progenitors are defective in systemic sclerosis. , 2006, Arthritis and rheumatism.

[22]  G. Higgins,et al.  Novel functions of intracellular IL-1ra in human dermal fibroblasts: implications in the pathogenesis of fibrosis. , 2006, The Journal of investigative dermatology.

[23]  T. Matsushita,et al.  Longitudinal analysis of serum cytokine concentrations in systemic sclerosis: association of interleukin 12 elevation with spontaneous regression of skin sclerosis. , 2006, The Journal of rheumatology.

[24]  U. Banning,et al.  The Role of IL-4 and IL-12 in the Regulation of Collagen Synthesis by Fibroblasts , 2006, Immunological investigations.

[25]  C. Denton,et al.  Circulating levels of active transforming growth factor beta1 are reduced in diffuse cutaneous systemic sclerosis and correlate inversely with the modified Rodnan skin score. , 2005, Rheumatology.

[26]  L. Settas,et al.  Early T cell activation in the skin from patients with systemic sclerosis , 2005, Annals of the rheumatic diseases.

[27]  U. Müller-Ladner,et al.  Expression of interleukin-21 receptor in epidermis from patients with systemic sclerosis. , 2005, Arthritis and rheumatism.

[28]  F. Sampogna,et al.  Cytokine and chemokine levels in systemic sclerosis: relationship with cutaneous and internal organ involvement , 2004, Clinical and experimental immunology.

[29]  Toshiyuki Yamamoto,et al.  Upregulation of Interleukin-13 and Its Receptor in a Murine Model of Bleomycin-Induced Scleroderma , 2004, International Archives of Allergy and Immunology.

[30]  Simon C Watkins,et al.  Autocrine activation by interleukin 1alpha induces the fibrogenic phenotype of systemic sclerosis fibroblasts. , 2004, The Journal of rheumatology.

[31]  Shinichi Sato,et al.  Serum levels of a Th1 chemoattractant IP-10 and Th2 chemoattractants, TARC and MDC, are elevated in patients with systemic sclerosis. , 2004, Journal of dermatological science.

[32]  Shinichi Sato,et al.  Augmented production of transforming growth factor-β by cultured peripheral blood mononuclear cells from patients with systemic sclerosis , 2004, Archives of Dermatological Research.

[33]  M. Aringer,et al.  Increased transendothelial migration of scleroderma lymphocytes , 2004, Annals of the rheumatic diseases.

[34]  S. Jimenez,et al.  Following the Molecular Pathways toward an Understanding of the Pathogenesis of Systemic Sclerosis , 2004, Annals of Internal Medicine.

[35]  J. Dayer,et al.  Systemic sclerosis Th2 cells inhibit collagen production by dermal fibroblasts via membrane-associated tumor necrosis factor alpha. , 2003, Arthritis and rheumatism.

[36]  R. Scrivo,et al.  Interleukin-13 in systemic sclerosis: relationship to nailfold capillaroscopy abnormalities , 2003, Clinical Rheumatology.

[37]  N. Mukaida,et al.  Abnormal expression of intracellular cytokines and chemokine receptors in peripheral blood T lymphocytes from patients with systemic sclerosis , 2002, Clinical and experimental immunology.

[38]  H. Ihn,et al.  Increased transcriptional activities of transforming growth factor beta receptors in scleroderma fibroblasts. , 2002, Arthritis and rheumatism.

[39]  J. Varga.  Scleroderma and Smads: dysfunctional Smad family dynamics culminating in fibrosis. , 2002, Arthritis and rheumatism.

[40]  S. Jimenez,et al.  Oligoclonal T Cell Expansion in the Skin of Patients with Systemic Sclerosis1 , 2002, The Journal of Immunology.

[41]  T. King,et al.  Elevation of soluble interleukin-2 receptor levels in the bronchoalveolar lavage from patients with systemic sclerosis , 2001, Rheumatology International.

[42]  M. Hasegawa,et al.  Serum levels of interleukin-6 and interleukin-10 correlate with total skin thickness score in patients with systemic sclerosis. , 2001, Journal of dermatological science.

[43]  K. Esposito,et al.  Peripheral Blood T Lymphocytes from Systemic Sclerosis Patients Show Both Th1 and Th2 Activation , 2001, Journal of Clinical Immunology.

[44]  M. Hasegawa,et al.  Levels of interleukin 12, a cytokine of type 1 helper T cells, are elevated in sera from patients with systemic sclerosis. , 2000, The Journal of rheumatology.

[45]  K. Takabayashi,et al.  Increased interleukin-17 production in patients with systemic sclerosis. , 2000, Arthritis and rheumatism.

[46]  J. Korn,et al.  Role of apoptosis and transforming growth factor beta1 in fibroblast selection and activation in systemic sclerosis. , 2000, Arthritis and rheumatism.

[47]  S. Sa,et al.  Tumor Necrosis Factor α Suppresses the Induction of Connective Tissue Growth Factor by Transforming Growth Factor-β in Normal and Scleroderma Fibroblasts* , 2000, The Journal of Biological Chemistry.

[48]  R. D. du Bois,et al.  Different cytokine profiles in cryptogenic fibrosing alveolitis and fibrosing alveolitis associated with systemic sclerosis: a quantitative study of open lung biopsies. , 1999, The European respiratory journal.

[49]  R. Rezzonico,et al.  Inhibition of type I collagen production by dermal fibroblasts upon contact with activated T cells: different sensitivity to inhibition between systemic sclerosis and control fibroblasts. , 1998, Arthritis and rheumatism.

[50]  H. Fujisawa,et al.  Enhanced interleukin 6 production by cultured fibroblasts from patients with systemic sclerosis in response to platelet derived growth factor. , 1998, The Journal of rheumatology.

[51]  K. Stengaard-Pedersen,et al.  Soluble intercellular adhesion molecule-1 (sICAM-1) and soluble interleukin-2 receptors (sIL-2R) in scleroderma skin. , 1998, British journal of rheumatology.

[52]  H. Ihn,et al.  Increased production of interleukin 6 and interleukin 8 in scleroderma fibroblasts. , 1998, The Journal of rheumatology.

[53]  M. Fujimoto,et al.  Serum levels of interleukin 6 (IL-6), oncostatin M, soluble IL-6 receptor, and soluble gp130 in patients with systemic sclerosis. , 1998, The Journal of rheumatology.

[54]  G. Pizzolo,et al.  Type 2 helper T-cell predominance and high CD30 expression in systemic sclerosis. , 1997, The American journal of pathology.

[55]  U. Haustein,et al.  In situ expression and serum levels of tumor necrosis factor-alpha receptors in patients with early stages of systemic sclerosis. , 1997, The Journal of rheumatology.

[56]  M. Fujimoto,et al.  Elevated serum tumor necrosis factor-alpha levels in patients with systemic sclerosis: association with pulmonary fibrosis. , 1997, The Journal of rheumatology.

[57]  M. Di Franco,et al.  Circulating levels of soluble CD30 are increased in patients with systemic sclerosis (SSc) and correlate with serological and clinical features of the disease , 1997, Clinical and experimental immunology.

[58]  R. Silver,et al.  Cytokine concentrations in bronchoalveolar lavage fluid of patients with systemic sclerosis. , 1997, Arthritis and rheumatism.

[59]  M. Gruschwitz,et al.  Up-regulation of class II major histocompatibility complex and intercellular adhesion molecule 1 expression on scleroderma fibroblasts and endothelial cells by interferon-gamma and tumor necrosis factor alpha in the early disease stage. , 1997, Arthritis and rheumatism.

[60]  M. Fujimoto,et al.  Elevated serum levels of interleukin 4 (IL-4), IL-10, and IL-13 in patients with systemic sclerosis. , 1997, The Journal of rheumatology.

[61]  T. Medsger,et al.  Soluble serum interleukin 2 receptors in patients with systemic sclerosis. , 1996, The Journal of rheumatology.

[62]  R. Giacomelli,et al.  Peripheral blood mononuclear cells of patients with systemic sclerosis produce increased amounts of interleukin 6, but not transforming growth factor beta 1. , 1996, The Journal of rheumatology.

[63]  C. Strange,et al.  Elevated levels of platelet derived growth factor and transforming growth factor-beta 1 in bronchoalveolar lavage fluid from patients with scleroderma. , 1995, The Journal of rheumatology.

[64]  H. Ihn,et al.  Growth regulation in scleroderma fibroblasts: increased response to transforming growth factor-beta 1. , 1995, The Journal of investigative dermatology.

[65]  B. Kirkham,et al.  Circulating interleukin 1 beta and soluble interleukin 2 receptor: evaluation as markers of disease activity in scleroderma. , 1995, The Journal of rheumatology.

[66]  A. Herrick,et al.  Plasma TGF beta in systemic sclerosis: a cross-sectional study. , 1994, Annals of the rheumatic diseases.

[67]  D. Puett,et al.  Rapid exacerbation of scleroderma in a patient treated with interleukin 2 and lymphokine activated killer cells for renal cell carcinoma. , 1994, Journal of Rheumatology.

[68]  S. Todesco,et al.  Early phenotypic activation of circulating helper memory T cells in scleroderma: correlation with disease activity. , 1993, Annals of the rheumatic diseases.

[69]  L. Rudnicka,et al.  Adhesion of peripheral blood mononuclear cells to vascular endothelium in patients with systemic sclerosis (scleroderma). , 1992, Arthritis & Rheumatism.

[70]  M. Trojanowska,et al.  Selective upregulation of platelet-derived growth factor alpha receptors by transforming growth factor beta in scleroderma fibroblasts , 1992, The Journal of experimental medicine.

[71]  J. Banchereau,et al.  Interleukin-4 stimulates collagen synthesis by normal and scleroderma fibroblasts in dermal equivalents. , 1992, Cellular and molecular biology.

[72]  C. Clavel,et al.  Gamma-interferon inhibits extracellular matrix synthesis and remodeling in collagen lattice cultures of normal and scleroderma skin fibroblasts. , 1992, European journal of cell biology.

[73]  A. Freemont,et al.  Sequential dermal microvascular and perivascular changes in the development of scleroderma , 1992, The Journal of pathology.

[74]  B. Amor,et al.  Abnormalities of T lymphocyte subsets in systemic sclerosis demonstrated with anti-CD45RA and anti-CD29 monoclonal antibodies. , 1991, Annals of the rheumatic diseases.

[75]  R. Cattaneo,et al.  Increased concentrations of soluble interleukin-2 receptor in the serum of patients with systemic sclerosis. , 1991, Annals of the rheumatic diseases.

[76]  A. Santoni,et al.  Soluble interleukin‐2 receptor, interleukin‐2 and interleukin‐4 in sera and supernatants from patients with progressive systemic sclerosis , 1990, Clinical and experimental immunology.

[77]  D. Furst,et al.  Elevated serum levels of soluble interleukin 2 receptor, interleukin 2 and neopterin in diffuse and limited scleroderma: effects of chlorambucil. , 1990, The Journal of rheumatology.

[78]  V. Falanga,et al.  Observations in the Potential Role of Transforming Growth Factor‐β in Cutaneous Fibrosis: Systemic Sclerosis a , 1990, Annals of the New York Academy of Sciences.

[79]  T. Whiteside,et al.  Functional and phenotypic analysis of T lymphocytes cloned from the skin of patients with systemic sclerosis , 1990, Clinical and experimental immunology.

[80]  M. Kahaleh,et al.  Interleukin-2 in scleroderma: correlation of serum level with extent of skin involvement and disease duration. , 1989, Annals of internal medicine.

[81]  T. Medsger,et al.  Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis. , 1988, Arthritis and rheumatism.

[82]  R. Fine.  Cytotoxicity of sera from patients with scleroderma--effects on human endothelial cells and fibroblasts in culture. , 1984, International journal of dermatology.

[83]  T. Whiteside,et al.  Lymphocytes in the skin of patients with progressive systemic sclerosis. Quantification, subtyping, and clinical correlations. , 1984, Arthritis and rheumatism.

[84]  M. Kahaleh,et al.  Endothelial injury in scleroderma , 1979, The Journal of experimental medicine.

[85]  J. R. Reeves,et al.  Cellular infiltrates in scleroderma skin. , 1977, Arthritis and rheumatism.

[86]  M. Fujimoto,et al.  Increased serum interleukin 23 in patients with systemic sclerosis. , 2008, The Journal of rheumatology.

[87]  S. R. Utiyama,et al.  Analysis of lymphocyte subpopulations in systemic sclerosis. , 2003, Journal of investigational allergology & clinical immunology.

[88]  N. Kamatani,et al.  Association of IL1A gene polymorphisms with susceptibility to and severity of systemic sclerosis in the Japanese population. , 2003, Arthritis and rheumatism.

[89]  H. Okamura,et al.  Interleukin-18 regulates both Th1 and Th2 responses. , 2001, Annual review of immunology.

[90]  K. Yamane,et al.  Blockade of endogenous transforming growth factor beta signaling prevents up-regulated collagen synthesis in scleroderma fibroblasts: association with increased expression of transforming growth factor beta receptors. , 2001, Arthritis and rheumatism.

[91]  M. Matucci-Cerinic,et al.  Circulating gamma/delta T lymphocytes from systemic sclerosis (SSc) patients display a T helper (Th) 1 polarization. , 2001, Clinical and experimental immunology.

[92]  T. Wright,et al.  Endogenous IL-1alpha from systemic sclerosis fibroblasts induces IL-6 and PDGF-A. , 1999, The Journal of clinical investigation.

[93]  H. Ihn,et al.  Increased expression of TGF-beta receptors by scleroderma fibroblasts: evidence for contribution of autocrine TGF-beta signaling to scleroderma phenotype. , 1998, The Journal of investigative dermatology.

[94]  D. Dean,et al.  Regulation of vascular cell adhesion molecule-1 expression by IL-4 and TNF-alpha in cultured endothelial cells. , 1995, The Journal of clinical investigation.

[95]  E. Leroy,et al.  Different effects of basic fibroblast growth factor and transforming growth factor-beta on the two platelet-derived growth factor receptors' expression in scleroderma and healthy human dermal fibroblasts. , 1995, The Journal of investigative dermatology.

[96]  S. Jimenez,et al.  Mononuclear cellular infiltrates in clinically involved skin from patients with systemic sclerosis of recent onset predominantly consist of monocytes/macrophages. , 1995, Pathobiology : journal of immunopathology, molecular and cellular biology.

[97]  R. Vancheeswaran,et al.  Immunocytochemical localization and serologic detection of transforming growth factor beta 1. Association with type I procollagen and inflammatory cell markers in diffuse and limited systemic sclerosis, morphea, and Raynaud's phenomenon. , 1994, Arthritis and rheumatism.

[98]  F. Wigley,et al.  Interleukin-1, interleukin-2, interleukin-4, interleukin-6, tumor necrosis factor alpha, and interferon-gamma levels in sera from patients with scleroderma. , 1992, Arthritis and rheumatism.

[99]  F. Wigley,et al.  Interleukin-1, interleukin-2, interleukin-4, interleukin-6, tumor necrosis factor alpha, and interferon-gamma levels in sera from patients with scleroderma. , 1992, Arthritis and rheumatism.

[100]  S. Durum,et al.  Interleukin 1: an immunological perspective. , 1985, Annual review of immunology.